Comparison of the aerosol velocity and spray duration of Respimat Soft Mist inhaler and pressurized metered dose inhalers
- PMID: 16181002
- DOI: 10.1089/jam.2005.18.273
Comparison of the aerosol velocity and spray duration of Respimat Soft Mist inhaler and pressurized metered dose inhalers
Abstract
Apart from particle size distribution, spray velocity is one of the most important aerosol characteristics that influence lung deposition of inhaled drugs. The time period over which the aerosol is released (spray duration) is also important for coordination of inhalation. Respimat Soft Mist Inhaler (SMI) is a new generation, propellant-free inhaler that delivers drug to the lung much more efficiently than pressurised metered dose inhalers (pMDIs). The objective of this study was to compare the velocity and spray duration of aerosol clouds produced by Respimat SMI with those from a variety of chlorofluorocarbon (CFC) and hydrofluoroalkane (HFA) pMDIs. All inhalers contained solutions or suspensions of bronchodilators. A videorecording method was used to determine the aerosol velocity. For spray duration, the time for generation of the Soft Mist by Respimat SMI was initially determined using three different methods (videorecording [techniques A and B], laser light diffraction and rotating disc). Videorecording was then used to compare the spray duration of Respimat SMI with those from the other inhalers. The Soft Mist produced by Respimat SMI moved much more slowly and had a more prolonged duration than aerosol clouds from pMDIs (mean velocity at a 10-cm distance from the nozzle: Respimat SMI, 0.8 m/sec; pMDIs, 2.0-8.4 m/sec; mean duration: Respimat SMI, 1.5 sec; pMDIs, 0.15-0.36 sec). These characteristics should result in improved lung and reduced oropharyngeal deposition, and are likely to simplify coordination of inhaler actuation and inhalation compared with pMDIs.
Comment in
-
Aerosol plumes: slow and steady wins the race.J Aerosol Med. 2005 Fall;18(3):261-3. doi: 10.1089/jam.2005.18.261. J Aerosol Med. 2005. PMID: 16181000 No abstract available.
Similar articles
-
Higher lung deposition with Respimat Soft Mist inhaler than HFA-MDI in COPD patients with poor technique.Int J Chron Obstruct Pulmon Dis. 2008;3(4):763-70. Int J Chron Obstruct Pulmon Dis. 2008. PMID: 19281091 Free PMC article. Clinical Trial.
-
A review of the development of Respimat Soft Mist Inhaler.Int J Pharm. 2004 Sep 28;283(1-2):1-9. doi: 10.1016/j.ijpharm.2004.06.018. Int J Pharm. 2004. PMID: 15363496 Review.
-
A review of ipratropium bromide/fenoterol hydrobromide (Berodual) delivered via Respimat Soft Mist Inhaler in patients with asthma and chronic obstructive pulmonary disease.Drugs. 2004;64(15):1671-82. doi: 10.2165/00003495-200464150-00005. Drugs. 2004. PMID: 15257628 Review.
-
Reduced Environmental Impact of the Reusable Respimat® Soft Mist™ Inhaler Compared with Pressurised Metered-Dose Inhalers.Adv Ther. 2019 Sep;36(9):2487-2492. doi: 10.1007/s12325-019-01028-y. Epub 2019 Jul 17. Adv Ther. 2019. PMID: 31317391 Free PMC article.
-
Efficacy and safety of ipratropium bromide plus fenoterol inhaled via Respimat Soft Mist Inhaler vs. a conventional metered dose inhaler plus spacer in children with asthma.Pediatr Pulmonol. 2004 Mar;37(3):264-72. doi: 10.1002/ppul.10428. Pediatr Pulmonol. 2004. PMID: 14966821 Clinical Trial.
Cited by
-
Validating CFD Predictions of Pharmaceutical Aerosol Deposition with In Vivo Data.Pharm Res. 2015 Oct;32(10):3170-87. doi: 10.1007/s11095-015-1695-1. Epub 2015 May 6. Pharm Res. 2015. PMID: 25944585 Free PMC article.
-
Scale-Up and Postapproval Changes in Orally Inhaled Drug Products: Scientific and Regulatory Considerations.J Aerosol Med Pulm Drug Deliv. 2025 Apr;38(2):39-63. doi: 10.1089/jamp.2024.0036. Epub 2024 Dec 9. J Aerosol Med Pulm Drug Deliv. 2025. PMID: 39648823 Review.
-
Lung Deposition and Inspiratory Flow Rate in Patients with Chronic Obstructive Pulmonary Disease Using Different Inhalation Devices: A Systematic Literature Review and Expert Opinion.Int J Chron Obstruct Pulmon Dis. 2021 Apr 19;16:1021-1033. doi: 10.2147/COPD.S297980. eCollection 2021. Int J Chron Obstruct Pulmon Dis. 2021. PMID: 33907390 Free PMC article.
-
Drug-targeting methodologies with applications: A review.World J Clin Cases. 2014 Dec 16;2(12):742-56. doi: 10.12998/wjcc.v2.i12.742. World J Clin Cases. 2014. PMID: 25516850 Free PMC article. Review.
-
Respiratory delivered vaccines: Current status and perspectives in rational formulation design.Acta Pharm Sin B. 2024 Dec;14(12):5132-5160. doi: 10.1016/j.apsb.2024.08.026. Epub 2024 Nov 4. Acta Pharm Sin B. 2024. PMID: 39807330 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources